Detalles de la búsqueda
1.
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Clin Pharmacokinet
; 63(4): 423-438, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38609704
2.
Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective ß3-Adrenoceptor Agonist, in Human Liver Microsomes.
Eur J Drug Metab Pharmacokinet
; 43(3): 301-309, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164523
3.
Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
Drug Metab Dispos
; 34(11): 1811-6, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16882764
4.
The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
Drug Metab Dispos
; 34(5): 800-6, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16473917
5.
Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection.
Biomed Chromatogr
; 18(9): 667-72, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15386500
Resultados
1 -
5
de 5
1
Próxima >
>>